Valuation: Atossa Therapeutics, Inc.

Market Cap 19.46M 17.01M 15.72M 14.53M 27.35M 1.87B 27.85M 187M 73.56M 915M 73.1M 71.49M 3.15B P/E 2026 *
-0.52x
P/E 2027 * -0.65x
Enterprise Value 19.46M 17.01M 15.72M 14.53M 27.35M 1.87B 27.85M 187M 73.56M 915M 73.1M 71.49M 3.15B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-5.83%
1 week-9.24%
Current month+17.10%
1 month-8.13%
3 months-57.76%
6 months-74.97%
Current year-74.46%
1 week 2.21
Extreme 2.21
2.42
1 month 1.7
Extreme 1.7
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
87.3
10 years 1.7
Extreme 1.7
806.76
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
05-12Free

Director

10,000 0.1161%
05-12
Ensisheim Partners LLC
OtherCompany 0 0%
05-12Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-5.83%-9.24%-83.91%-87.85% 19.46M
-0.76%+0.91%+2.59%+6.84% 50.35B
+0.55%-2.88%+382.07%+593.81% 39.32B
+0.13%-0.19%+29.79%-6.00% 34.69B
+0.86%-0.78%+21.58%+56.15% 34.08B
-1.31%-3.03%+2.51%+25.24% 26.63B
+0.13%-0.52% - - 16.49B
+1.13%-1.85%+67.36%+120.46% 15.31B
+0.55%+3.43%+15.06%+18.08% 13.8B
+1.13%-0.44%+12.34%-31.79% 12.87B
Average -0.35%-1.66%+49.93%+77.21% 24.36B
Weighted average by Cap. +0.10%-0.73%+80.98%+122.24%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.68M -30.21M -27.91M -52.56M -3.59B -53.51M -360M -141M -1.76B -140M -137M -6.06B -39.31M -34.36M -31.76M -29.34M -55.26M -3.78B -56.26M -379M -149M -1.85B -148M -144M -6.37B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
14/07/26 US$2.260 -5.83% 157,797
13/07/26 US$2.400 +1.27% 177,603
10/07/26 US$2.370 +0.42% 65,745
09/07/26 US$2.360 -3.67% 144,165
08/07/26 US$2.450 -1.61% 127,999
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.260USD
Average target price
22.00USD
Spread / Average Target
+873.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock